Send to

Choose Destination
Transl Oncol. 2012 Dec;5(6):398-403. Epub 2012 Dec 1.

Gene signatures in breast cancer: current and future uses.

Author information

Servicio de Oncología Médica, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.


Gene signatures have been developed for estrogen receptor-positive breast cancer to complement pathological factors in providing prognostic information. The 70-gene and the 21-gene signatures identify patients who may not require adjuvant chemotherapy. Gene signatures in triple-negative disease and HER2-positive disease have not been fully developed yet, although studies demonstrate heterogeneity within these subgroups. Further research is needed before genotyping will help in making clinical decisions in triple-negative and HER2-positive disease. Molecular subtyping of breast cancer led to define luminal, basal, and HER2-enriched subtypes, which have specific clinical behavior. This approach may lead to identify new subgroups requiring specific therapies. Standardization of techniques will be required to translate investigations to the clinic.


Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center